Skip to main content
Erschienen in: Journal of Clinical Immunology 4/2009

01.07.2009

Imbalances Between Interleukin-1 and Tumor Necrosis Factor Agonists and Antagonists in Stable COPD

verfasst von: Elizabeth Sapey, Ali Ahmad, Darren Bayley, Paul Newbold, Noel Snell, Paul Rugman, Robert A. Stockley

Erschienen in: Journal of Clinical Immunology | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNFα) are potentially important in Chronic Obstructive Pulmonary Disease (COPD), but little is known of the relationships between these cytokines and their antagonists in disease compared with healthy controls. It is unclear if concentrations relate to disease severity. The study aimed to investigate these relationships and to assess the potential activity of each cytokine in the context of their antagonists.

Methods

Plasma cytokines, soluble receptors, and cell counts were measured in patients with stable COPD and age-matched healthy controls (n = 15 for both) daily for 5 days; these mediators were also measured in corresponding sputum samples from the COPD patients.

Results

COPD patients had significantly reduced concentrations of the antagonists, IL-1sRII, and IL-1RA compared with controls. In COPD, IL-1β exceeded its antagonists and correlated significantly with BMI and FEV1, while plasma IL-1RA correlated positively with BMI but negatively with sputum IL-1β, neutrophil, and macrophage counts and smoking history. TNFα antagonists exceeded agonists in both groups and did not correlate with COPD severity.

Conclusions

Endogenous IL-1β antagonists appear reduced in COPD. Furthermore, IL-1β correlated with clinical aspects of disease severity, suggesting that IL-1β may play a critical role in COPD. Given the relevant concentrations and binding affinities, it is likely that TNFα has limited activity in stable COPD.
Literatur
1.
Zurück zum Zitat Aaron SD, Angel JB, Lunau M, Wright K, Fex C, Le Saux N, Dales RE. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:349–55.PubMed Aaron SD, Angel JB, Lunau M, Wright K, Fex C, Le Saux N, Dales RE. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:349–55.PubMed
3.
Zurück zum Zitat Sapey E, Bayley DL, Ahmad A, Newbold P, Snell N, Stockley RA. Inter-relationships between inflammatory markers in stable COPD patients with bronchitis: the intra and inter patient variability. Thorax 2008;63:493–9. doi:10.1136/thx.2007.086751.PubMedCrossRef Sapey E, Bayley DL, Ahmad A, Newbold P, Snell N, Stockley RA. Inter-relationships between inflammatory markers in stable COPD patients with bronchitis: the intra and inter patient variability. Thorax 2008;63:493–9. doi:10.​1136/​thx.​2007.​086751.PubMedCrossRef
5.
Zurück zum Zitat Lucey EC, Keane J, Kuang PP, Snider GL, Goldstein RH. Severity of elastase-induced emphysema is decreased in TNFα and IL-1ß receptor deficient mice. Lab Invest 2002;82:79–85.PubMed Lucey EC, Keane J, Kuang PP, Snider GL, Goldstein RH. Severity of elastase-induced emphysema is decreased in TNFα and IL-1ß receptor deficient mice. Lab Invest 2002;82:79–85.PubMed
6.
Zurück zum Zitat Lappalainen U, Whitsett JA, Wert SE, Tichelaar JW, Bry K. Interleukin-1beta causes pulmonary inflammation, emyphysema and airway remodelling in the adult murine lung. Am J Respir Cell Mol Biol 2005;32:311–8. doi:10.1165/rcmb.2004-0309OC.PubMedCrossRef Lappalainen U, Whitsett JA, Wert SE, Tichelaar JW, Bry K. Interleukin-1beta causes pulmonary inflammation, emyphysema and airway remodelling in the adult murine lung. Am J Respir Cell Mol Biol 2005;32:311–8. doi:10.​1165/​rcmb.​2004-0309OC.PubMedCrossRef
7.
Zurück zum Zitat Oudijk EJ, Nijhuis EH, Zwank MD, van d Graaf EA, Mager HJ, Coffer JW, Lammers JWJ, Koenderman L. Systemic inflammation in COPD visualised by gene profiling in peripheral blood neutrophils. Thorax 2005;60:538–44. doi:10.1136/thx.2004.034009.PubMedCrossRef Oudijk EJ, Nijhuis EH, Zwank MD, van d Graaf EA, Mager HJ, Coffer JW, Lammers JWJ, Koenderman L. Systemic inflammation in COPD visualised by gene profiling in peripheral blood neutrophils. Thorax 2005;60:538–44. doi:10.​1136/​thx.​2004.​034009.PubMedCrossRef
8.
Zurück zum Zitat Pitsiou G, Kyriazis G, Hatzizisi O, Argyropoulou P, Mavrofridis E. Tumour necrosis factor alpha serum levels, weight loss and tissue oxygenation in chronic obstructive pulmonary disease. Respir Med 2002;96:594–8. doi:10.1053/rmed.2002.1322.PubMedCrossRef Pitsiou G, Kyriazis G, Hatzizisi O, Argyropoulou P, Mavrofridis E. Tumour necrosis factor alpha serum levels, weight loss and tissue oxygenation in chronic obstructive pulmonary disease. Respir Med 2002;96:594–8. doi:10.​1053/​rmed.​2002.​1322.PubMedCrossRef
9.
Zurück zum Zitat Eid AA, Ionescu AA, Nixon LS, Lewis-Jenkins V, Matthews SB, Griffiths TL, Shale DL. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;15(164):1414–8. Eid AA, Ionescu AA, Nixon LS, Lewis-Jenkins V, Matthews SB, Griffiths TL, Shale DL. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;15(164):1414–8.
11.
Zurück zum Zitat Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management and prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256–76.PubMed Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management and prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256–76.PubMed
13.
Zurück zum Zitat Mikami M, Llewellyn-Jones CG, Bayley D, Stockley RA. The chemotactic activity of sputum from patients with bronchiectasis. Am J Respir Crit Care Med 1998;157:723–8.PubMed Mikami M, Llewellyn-Jones CG, Bayley D, Stockley RA. The chemotactic activity of sputum from patients with bronchiectasis. Am J Respir Crit Care Med 1998;157:723–8.PubMed
17.
Zurück zum Zitat Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196–204.PubMed Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196–204.PubMed
18.
Zurück zum Zitat Gamble E, Qiu Y, Wang D, Zhu J, Vignola AM, Kroegel C, Morell F, Hansel TT, Pavord I, Rabe KF, Barnes NC, Jeffrey PK. Variability of bronchial inflammation in chronic obstructive pulmonary disease: implications for study design. Eur Respir J 2006;27:293–9. doi:10.1183/09031936.06.00027705.PubMedCrossRef Gamble E, Qiu Y, Wang D, Zhu J, Vignola AM, Kroegel C, Morell F, Hansel TT, Pavord I, Rabe KF, Barnes NC, Jeffrey PK. Variability of bronchial inflammation in chronic obstructive pulmonary disease: implications for study design. Eur Respir J 2006;27:293–9. doi:10.​1183/​09031936.​06.​00027705.PubMedCrossRef
20.
Zurück zum Zitat Cannon JG, Abad LW, Vannier E, Lynch EA. Menstrual and gender dependent variations in circulating IL-1 agonists, antagonists and binding proteins. J Leukoc Biol 1998;63:117–23.PubMed Cannon JG, Abad LW, Vannier E, Lynch EA. Menstrual and gender dependent variations in circulating IL-1 agonists, antagonists and binding proteins. J Leukoc Biol 1998;63:117–23.PubMed
23.
Zurück zum Zitat Janson RW, King TE, Hance KR, Arend WP. Enhanced production of IL-1 receptor antagonist by alveolar macrophages from patients with interstitial lung disease. Am Rev Respir Dis 1993;148:495–503.PubMed Janson RW, King TE, Hance KR, Arend WP. Enhanced production of IL-1 receptor antagonist by alveolar macrophages from patients with interstitial lung disease. Am Rev Respir Dis 1993;148:495–503.PubMed
25.
Zurück zum Zitat Rolfe MW, Standifrod TJ, Kunkel SL, Burdick MD, Gilbert AR, Lynch JP 3rd, Streiter RM. Interleukin-1 receptor antagonist expression in sarcoidosis. Am Rev Dis 1993;148:1378–84. Rolfe MW, Standifrod TJ, Kunkel SL, Burdick MD, Gilbert AR, Lynch JP 3rd, Streiter RM. Interleukin-1 receptor antagonist expression in sarcoidosis. Am Rev Dis 1993;148:1378–84.
32.
Zurück zum Zitat Burger D, Chicheportiche R, Giri J, Dayer JM. The inhibitory effect of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 receptor and hindered by type 1 interleukin-1 receptor. J Clin Invest 1995;96:38–41. doi:10.1172/JCI118045.PubMedCrossRef Burger D, Chicheportiche R, Giri J, Dayer JM. The inhibitory effect of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 receptor and hindered by type 1 interleukin-1 receptor. J Clin Invest 1995;96:38–41. doi:10.​1172/​JCI118045.PubMedCrossRef
33.
Zurück zum Zitat Lennard AC. Interleukin-1 receptor antagonist. Crit Rev Immunol 1995;15:77–105.PubMed Lennard AC. Interleukin-1 receptor antagonist. Crit Rev Immunol 1995;15:77–105.PubMed
34.
Zurück zum Zitat Kurrie R, Lauffer L, Roder J, Kanzey EJ, Enssle KH, Seiler FR. Regulation of IL-1 activity by soluble IL-1 receptors. Behring Inst Mitt 1995;96:45–57. Kurrie R, Lauffer L, Roder J, Kanzey EJ, Enssle KH, Seiler FR. Regulation of IL-1 activity by soluble IL-1 receptors. Behring Inst Mitt 1995;96:45–57.
35.
Zurück zum Zitat Granowitz EV, Clark BD, Mancilla J, Dinarello CA. Interleukin 1 receptor antagonist competitively inhibits the binding of interleukin-1 to the Interleukin 1 Receptor. J Biol Chem 1991;266:14147–50.PubMed Granowitz EV, Clark BD, Mancilla J, Dinarello CA. Interleukin 1 receptor antagonist competitively inhibits the binding of interleukin-1 to the Interleukin 1 Receptor. J Biol Chem 1991;266:14147–50.PubMed
36.
Zurück zum Zitat Giri JG, Newton RC, Horuk R. Identification of soluble interleukin 1 binding protein in cell free supernatant. J Biol Chem 1990;265:17416–9.PubMed Giri JG, Newton RC, Horuk R. Identification of soluble interleukin 1 binding protein in cell free supernatant. J Biol Chem 1990;265:17416–9.PubMed
37.
Zurück zum Zitat Dubost JJ, Perrier S, Afane M, Viallard JL, Roux-Lombard P, Baudet-Pommel M, Begue C, Kemeny JL, Sauvezie B. IL-1 receptor antagonist in saliva; characterization in normal saliva and reduced concentration in Sjogren’s Syndrome. Clin Exp Immunol 1996;106:237–42. doi:10.1046/j.1365-2249.1996.d01-824.x.PubMedCrossRef Dubost JJ, Perrier S, Afane M, Viallard JL, Roux-Lombard P, Baudet-Pommel M, Begue C, Kemeny JL, Sauvezie B. IL-1 receptor antagonist in saliva; characterization in normal saliva and reduced concentration in Sjogren’s Syndrome. Clin Exp Immunol 1996;106:237–42. doi:10.​1046/​j.​1365-2249.​1996.​d01-824.​x.PubMedCrossRef
38.
Zurück zum Zitat Sabit R, Bolton CE, Edwards PH, Pettit RJ, Evans WD, McEniery CM, Wilkinson IB, Cockcroft JR, Shale DJ. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:1259–65. doi:10.1164/rccm.200701-067OC.PubMedCrossRef Sabit R, Bolton CE, Edwards PH, Pettit RJ, Evans WD, McEniery CM, Wilkinson IB, Cockcroft JR, Shale DJ. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:1259–65. doi:10.​1164/​rccm.​200701-067OC.PubMedCrossRef
41.
Zurück zum Zitat Beutler B, Milsark IW, Cerami A. Calchectin/tumour necrosis factor: production, distribution and metabolic fate in vivo. J Immunol 1985;135:3972–7.PubMed Beutler B, Milsark IW, Cerami A. Calchectin/tumour necrosis factor: production, distribution and metabolic fate in vivo. J Immunol 1985;135:3972–7.PubMed
42.
Zurück zum Zitat Girardin E, Roux-Lombard P, Grau GE, Suter P, Gallati H, Dayer JM. Imbalance between TNFa and soluble TNF receptor concentrations in severe meningococcaemia. The J5 Study Group. Immunology 1994;76:20–3. Girardin E, Roux-Lombard P, Grau GE, Suter P, Gallati H, Dayer JM. Imbalance between TNFa and soluble TNF receptor concentrations in severe meningococcaemia. The J5 Study Group. Immunology 1994;76:20–3.
43.
Zurück zum Zitat Aderka D, Engelmann H, Wallach D. Soluble TNF receptors in health and disease. In: Fiers W, Buurman WA, editors. Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance. Basel: Karger; 1993. p. 191–8. Aderka D, Engelmann H, Wallach D. Soluble TNF receptors in health and disease. In: Fiers W, Buurman WA, editors. Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance. Basel: Karger; 1993. p. 191–8.
44.
Zurück zum Zitat Aderka D, Sorkine P, Abu-Abid S, Lev D, Setton A, Cope AP, Walloch D. Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion relevance to the pathophysiology of septic shock. J Clin Invest 1998;101:50–659. doi:10.1172/JCI694.CrossRef Aderka D, Sorkine P, Abu-Abid S, Lev D, Setton A, Cope AP, Walloch D. Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion relevance to the pathophysiology of septic shock. J Clin Invest 1998;101:50–659. doi:10.​1172/​JCI694.CrossRef
45.
Zurück zum Zitat Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, Mahler D, Saadeh C, Siler T, Snell P, Korenblat P, Smith W, Kaye M, Mandel M, Andrews C, Prabhu R, Donohue JF, Watt R, Lo KH, Schlenker-Herceg R, Barnathan ES, Murray J. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:926–34. doi:10.1164/rccm.200607-995OC.PubMedCrossRef Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, Mahler D, Saadeh C, Siler T, Snell P, Korenblat P, Smith W, Kaye M, Mandel M, Andrews C, Prabhu R, Donohue JF, Watt R, Lo KH, Schlenker-Herceg R, Barnathan ES, Murray J. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:926–34. doi:10.​1164/​rccm.​200607-995OC.PubMedCrossRef
46.
48.
Zurück zum Zitat de Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM. Elevated TNFα production by peripheral monocytes of weight losing COPD patients. Am J Respir Crit Care Med 1996;153:633–7.PubMed de Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM. Elevated TNFα production by peripheral monocytes of weight losing COPD patients. Am J Respir Crit Care Med 1996;153:633–7.PubMed
49.
Zurück zum Zitat Dal Negro RW, Micheletto C, Tognella S, Visconti M, Guerriero M, Sandri MF. A two stage logistic model based on the measurement of pro-inflammatory cytokines in bronchial secretions for assessing bacterial, viral and non-infectious origin of COPD exacerbations. COPD 2005;2:7–16. doi:10.1081/COPD-200050680.PubMedCrossRef Dal Negro RW, Micheletto C, Tognella S, Visconti M, Guerriero M, Sandri MF. A two stage logistic model based on the measurement of pro-inflammatory cytokines in bronchial secretions for assessing bacterial, viral and non-infectious origin of COPD exacerbations. COPD 2005;2:7–16. doi:10.​1081/​COPD-200050680.PubMedCrossRef
53.
Zurück zum Zitat Celli BR, Cote CG, Marin JM, Cassanova C, Montes de Oca M, Mendez RP, Pinto Plata V, Cabral HJ. The body mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005–12. doi:10.1056/NEJMoa021322.PubMedCrossRef Celli BR, Cote CG, Marin JM, Cassanova C, Montes de Oca M, Mendez RP, Pinto Plata V, Cabral HJ. The body mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005–12. doi:10.​1056/​NEJMoa021322.PubMedCrossRef
54.
Zurück zum Zitat Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996;153:1530–5.PubMed Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996;153:1530–5.PubMed
56.
Zurück zum Zitat Gamble E, Grootendorst DC, Hattotuwa K, O’Shaughnessy T, Ram FS, Qiu Y, Zhu J, Vignola AM, Kroegal C, Morell F, Pavord ID, Rabe KF, Jeffery PK, Barnes NC. Airway mucosal inflammation in COPD is similar in smokers and ex-smokers; a pooled analysis. Eur Respir J 2007;30:467–71. doi:10.1183/09031936.00013006.PubMedCrossRef Gamble E, Grootendorst DC, Hattotuwa K, O’Shaughnessy T, Ram FS, Qiu Y, Zhu J, Vignola AM, Kroegal C, Morell F, Pavord ID, Rabe KF, Jeffery PK, Barnes NC. Airway mucosal inflammation in COPD is similar in smokers and ex-smokers; a pooled analysis. Eur Respir J 2007;30:467–71. doi:10.​1183/​09031936.​00013006.PubMedCrossRef
Metadaten
Titel
Imbalances Between Interleukin-1 and Tumor Necrosis Factor Agonists and Antagonists in Stable COPD
verfasst von
Elizabeth Sapey
Ali Ahmad
Darren Bayley
Paul Newbold
Noel Snell
Paul Rugman
Robert A. Stockley
Publikationsdatum
01.07.2009
Verlag
Springer US
Erschienen in
Journal of Clinical Immunology / Ausgabe 4/2009
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-009-9286-8

Weitere Artikel der Ausgabe 4/2009

Journal of Clinical Immunology 4/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.